N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 4 ClinicalTrials.gov

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

Sponsor: Takeda • ClinicalTrials.gov ID: NCT06581328

Registry updated: 2026-10-20
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission). Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), participants will receive Vedolizumab as an infusion in the vein (called intravenously). After this, participants will receive Vedolizumab as an injection under the skin (called subcutaneously) for the rest of the treatment. Participants for whom the treatment does not seem to work well after 3.5 months (14 weeks) will stop treatment with Vedolizumab and can change to another treatment and also there will be additional required visits at 6 months (26 weeks) and at 1 year (52 weeks). All participants will be checked again 4.5 months (18 weeks) after their last treatment with Vedolizumab. During the study, participants will visit their study clinic several times.

Interventions

  • Vedolizumab IV (Drug)
    Vedolizumab IV infusion
  • Vedolizumab SC (Drug)
    Vedolizumab SC injection

Eligibility criteria

Inclusion Criteria To be eligible to participate in this study, participants must meet all the following criteria: 1. In the investigator's opinion, the participant can understand and comply with protocol requirements. 2. The participant signs and dates an electronic informed consent form (ICF) and any required privacy authorization prior to any study procedures. 3. The participant is 18 to 80 years of age at the time of signing the ICF. 4. The participant's immunization is up to date per vedolizumab US prescribing information (USPI). 5. Participants must meet the contraception recommendations. 6. The participant has a diagnosis of moderate to severely active UC or CD defined by the following: 1. CD: A Crohn's Disease Activity Index (CDAI) score of 220 to 450 and a SES-CD \>=6 (\>=4 if isolated ileal disease) at screening OR 2. UC: A complete Mayo score (MS) of 6 to 12 with endoscopy sub-score of 2 to 3 at screening. 7. UC or CD diagnosis established prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report. 8. Demonstrated an inadequate response to, loss of response to, or intolerance of at least one of the following agents: corticosteroids, immunomodulators, and/or advanced therapy. Exclusion Criteria Participants who meet any of the following exclusion criteria will be excluded from participation in this study: 1. Received approved or investigational anti-integrin antibodies (i.e., vedolizumab, natalizumab, efalizumab, etrolizumab, abrilumab \[AMG 181\]) at any time prior to screening. 2. Failed (primary or secondary nonresponse) on more than 2 prior advanced treatments. 3. Use of corticosteroid enemas/suppositories within 2 weeks prior to screening (for UC and CD). 4. In the investigator's opinion, the participant meets any contraindication, warnings and precautions, drug interactions, or special population considerations per the vedolizumab USPI, or has a medical history or known allergy, hypersensitivity, or intolerance to vedolizumab or its excipients. 5. Received any investigational biologic therapy \<= 6 months prior to screening. 6. The participant has received an advanced treatment for an approved indication other than CD or UC within 60 days prior to screening. a. Advanced therapies include tumor necrosis factor (TNF) inhibitors, 12/23 antagonists, janus kinase (JAK) inhibitors, and sphingosine-1-phosphate (S1P) receptor modulators. 7. The participant has any evidence of an active infection during screening. 8. Ileostomy, colostomy, severe or symptomatic stenosis of the intestine, or short bowel syndrome. 9. A surgical procedure requiring general anesthesia within 30 days prior to screening or planned or possible major surgery during the study period. 10. History of malignancy, except for adequately treated nonmetastatic basal cell skin cancer; adequately treated squamous cell skin cancer that has not recurred for at least 1 year before screening; and adequately treated cervical carcinoma in situ that has not recurred for at least 3 years before screening. Participants with a remote history of malignancy (e.g., \>10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and therapy received; this must be discussed with the sponsor on a case-by-case basis before enrollment. 11. Participants with any unstable or uncontrolled cardiovascular conditions, moderate to severe heart failure (New York Heart Association Class III or IV), pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurological, or other medical disorders that, in the investigator's opinion, would confound the study results or compromise participant safety. 12. Participants with active cerebral or meningeal disease, signs or symptoms or a history of progressive multifocal leukoencephalopathy (PML), or any other major neurological disorder, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease. 13. Participant is not on a stable dose of corticosteroid. 14. Has any of the following laboratory abnormalities during the screening period: (a) hemoglobin \<8 grams per deciliter (g/dL); (b) white blood cell (WBC) count \<3.0 × 10\^9 per liter (L); (c) lymphocyte count \<0.5 × 10\^9/L; (d) platelet count \<100 × 10\^9/L or \>1200 × 10\^9/L; (e) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3.0 × the upper limit of normal (ULN); or (f) alkaline phosphatase (ALP) \>1.5 × ULN. Historical laboratory data may be used for screening if available in the participant's electronic health record (EHR) within 6 weeks before screening.

Conditions

Ulcerative Colitis Crohn's Disease

Locations

  • Gastro Health — Birmingham, Alabama, United States
  • East View Medical Research — Mobile, Alabama, United States
  • AZ Gastro Care — Chandler, Arizona, United States
  • Spectrum Research Institute LLC — Gilbert, Arizona, United States
  • GI Alliance- Sun City — Sun City, Arizona, United States
  • UAMS Health Gastroenterology Clinic — Little Rock, Arkansas, United States
  • Gastroenterology and Liver Institute — Escondido, California, United States
  • Inland Empire Gastroenterology — Murrieta, California, United States
  • United Clinical Research Institute — Murrieta, California, United States
  • Digestive Health Institute — Newport Beach, California, United States
  • Knowledge Research Center — Orange, California, United States
  • Medical Associates Research Group, Inc. — San Diego, California, United States
  • Peak Gastroenterology Associates — Colorado Springs, Colorado, United States
  • Rocky Mountain Endocopy Centers LLC — Littleton, Colorado, United States
  • Access Research Institute — Brooksville, Florida, United States
  • Gastro Florida — Clearwater, Florida, United States
  • Doral Medical Research, LLC — Hialeah, Florida, United States
  • Digestive and Liver Center of Florida, P.A. — Kissimmee, Florida, United States
  • Gastro Health Research - Miami — Miami, Florida, United States
  • Endoscopic Research, Inc. — Orlando, Florida, United States
  • Orlando Health-Orlando Regional Medical Center — Orlando, Florida, United States
  • Digestive and Liver Center of Florida — Orlando, Florida, United States
  • Gastro Health Research - Pensacola — Pensacola, Florida, United States
  • West Central Gastroenterology d/b/a Gastro Florida — Pinellas Park, Florida, United States
  • Digestive Healthcare of Georgia — Atlanta, Georgia, United States
  • AGA GA Research LLC — Atlanta, Georgia, United States
  • Atlanta Center for Gastroenterology, P.C. — Decatur, Georgia, United States
  • Yapp, Rockford M.D. (Private Practice) — Downers Grove, Illinois, United States
  • GI Alliance - Glenview — Glenview, Illinois, United States
  • Gastroenterology and Internal Medicine Specialists, SC — Lake Barrington, Illinois, United States
  • Suburban Gastroenterology — Naperville, Illinois, United States
  • GI Partners of Illinois - Southwest Gastroenterology — Oak Lawn, Illinois, United States
  • Rockford Gastroenterology Associates, Ltd. — Rockford, Illinois, United States
  • Springfield Clinic — Springfield, Illinois, United States
  • Riverview Health — Westfield, Indiana, United States
  • Hutchinson Clinic — Hutchinson, Kansas, United States
  • Tri-State Gastroenterology Associates — Crestview Hills, Kentucky, United States
  • Baton Rouge General Medical Center - Bluebonnet Campus — Baton Rouge, Louisiana, United States
  • Combined Gastro LLC — Lafayette, Louisiana, United States
  • GI Alliance — Metairie, Louisiana, United States
  • Portland Gastroenterology Center — Portland, Maine, United States
  • Capital Digestive Care — Chevy Chase, Maryland, United States
  • Woodholme Gastroenterology — Glen Burnie, Maryland, United States
  • Gastro Health Research - Framingham — Framingham, Massachusetts, United States
  • Lucida Clinical Trials LLC — New Bedford, Massachusetts, United States
  • Gastroenterology Associates of Western Michigan, P.L.C. — Wyoming, Michigan, United States
  • Huron Gastro — Ypsilanti, Michigan, United States
  • MNGI Digestive Health, P.A. — Plymouth, Minnesota, United States
  • Delta Gastroenterology and Endoscopy Center — Southaven, Mississippi, United States
  • SSM Health Medical Group — Bridgeton, Missouri, United States
  • GI Associates Research, LLC — Columbia, Missouri, United States
  • Mid America Gastro Intestinal Consultants — Kansas City, Missouri, United States
  • St Charles Clinical Research — Weldon Spring, Missouri, United States
  • Advanced Research Institute — Reno, Nevada, United States
  • Presbyterian Health care services — Albuquerque, New Mexico, United States
  • Westchester Putnam Gastroenterology PC — Carmel, New York, United States
  • Five Towns Gastroenterology — Cedarhurst, New York, United States
  • IMIDeology — Elmhurst, New York, United States
  • Intercity Gastroenterology — Fresh Meadows, New York, United States
  • NYU Langone Long Island Clinical Research Associates — Lake Success, New York, United States
  • Lenox Hill Hospital — New York, New York, United States
  • New York Gastroenterology Associates — New York, New York, United States
  • Manhattan Clinical Research, LLC — New York, New York, United States
  • Gastroenterology Group of Rochester — Rochester, New York, United States
  • ProHealth (Seaford) (Optum) — Seaford, New York, United States
  • Syracuse VA Medical Center — Syracuse, New York, United States
  • Digestive Disease Medicine — Utica, New York, United States
  • Crystal Run (Optum) — West Nyack, New York, United States
  • Charlotte Gastroenterology and Hepatology, P.L.L.C — Charlotte, North Carolina, United States
  • Carolina Digestive Diseases — Greenville, North Carolina, United States
  • Pinehurst Medical Clinic Inc — Pinehurst, North Carolina, United States
  • Piedmont Healthcare — Statesville, North Carolina, United States
  • Wilmington Gastroenterology Associates — Wilmington, North Carolina, United States
  • Gastro Health Research - Cincinnati — Cincinnati, Ohio, United States
  • DSI Research Northridge LLC — Dayton, Ohio, United States
  • Gastro Health Research - Liberty Township — Liberty Township, Ohio, United States
  • Great Lakes Gastroenterology Research, LLC — Mentor, Ohio, United States
  • DSI Research LLC — Springboro, Ohio, United States
  • NorthShore Gastroenterology Research, LLC — Westlake, Ohio, United States
  • The Oregon Clinic, P.C. — Portland, Oregon, United States
  • University Gastroenterology — Providence, Rhode Island, United States
  • Palmetto Primary Care Physician Division of Gastroenterology — Summerville, South Carolina, United States
  • Sanford Center for Digestive Health — Sioux Falls, South Dakota, United States
  • Tri-Cities Gastroenterology — Kingsport, Tennessee, United States
  • The Clinical Trials Network CTNX LLC — El Paso, Texas, United States
  • Amel Med LLC — Georgetown, Texas, United States
  • Kelsey Research Foundation — Houston, Texas, United States
  • MedCare Pharma LLC — Houston, Texas, United States
  • Integrity Advanced Therapeutics — Houston, Texas, United States
  • Spring Clinical Research — Houston, Texas, United States
  • Gastro Health & Nutrition — Katy, Texas, United States
  • One of a Kind Clinical Research Center LLC — Kingwood, Texas, United States
  • West Texas Research Institute — Lubbock, Texas, United States
  • Texas Gastro Consultants — Tomball, Texas, United States
  • Digestive Research of Central Texas, LLC — Waco, Texas, United States
  • GI Alliance - Webster — Webster, Texas, United States
  • Advanced Research Institute — Ogden, Utah, United States
  • Gastroenterology Consultants of Southwest Virginia. — Roanoke, Virginia, United States
  • Centricity Research VIR - DBA IACT Health Virginia Gastroenterology Institute Research — Suffolk, Virginia, United States
  • TMPG Clinical Research — Williamsburg, Virginia, United States
  • GI Alliance — Bellevue, Washington, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record